Alzheimer’s Disease Alzheimer’s Disease has proven very difficult to treat through many of the trials’ attempts by both small and large biotechnology and biopharmaceutical companies. Analysts and investors are skeptical about all promised successes in defeating this disease. However,  knowing that we are in the middle of a biological scientific revolution we are keeping our eyes and ears open each and every time a firm, …

Akero Therapeutics Efruxifermin Positive Results in NASH Akero Therapeutics (AKRO) results of a 16-week analysis of secondary and exploratory endpoints in Phase 2a BALANCED study of its product efruxifermin (EFX), formerly known as AKR-001, in patients with nonalcoholic steatohepatitis (NASH) are beating everybody’s expectations, including Akero Therapeutics.    Of the 40 responders, the firm observed that 48% achieved at least a one-stage improvement in fibrosis without …

Celldex Therapeutics A few years ago Celldex Therapeutics (CLDX) was known for its superior pipeline products. The most promising product in the firm’s pipeline was Celldex’s lead drug designed to treat the untreatable terrible brain cancer known as glioblastoma multiforme. What excited oncologists and investors at the time were the successful results coming out from early- and mid-phase clinical trials. Then, all of a sudden, …

AstraZeneca Plc and Gilead Sciences Potential Merger News spread through the media announcing that AstraZeneca Plc (AZN) has approached Gilead Sciences (GILD) regarding a possible, potential merger. People familiar with the subject (we don’t know who they are) believe that such a merger, if it materializes, would be the highest healthcare business deal on record. As told, the story recounts that AstraZeneca got in touch …

Navidea Biopharmaceuticals Stock Soared Navidea Biopharmaceuticals (NAVB) stock price jumped from $1.27 to $3.04 this morning. The reason for the stock’s soaring, according to the firm’s press release, was that interim data from a trial have further corroborated Navidea’s hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls as well as in patients with active rheumatoid arthritis (RA). Furthermore, this imaging …

Moderna Postive News for mRNA-1273 Vaccine Against Novel Coronavirus (COVID-19) Moderna (MRNA) announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2 or COVID-19), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID) which is part of the National Institutes of Health (NIH). According to the firm’s press release, Immunogenicity data are currently available …

Sorrento Therapeutics Anti-SARS-CoV-2 Antibody STI-1499 Sorrento Therapeutics (SRNE) announced that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 (COVID-19) virus infection in an in vitro virus infection experiment at a very low antibody concentration. Sorrento has screened billions of antibodies in its proprietary G-MAB™ fully human antibody library and has so far identified hundreds of antibody candidates that bind the S1 subunit of the SARS-CoV-2 Spike protein. …

Alexion to Acquire Portola Alexion (ALXN) and Portola (PTLA) entered into a definitive merger agreement and Alexion acquired Portola. The Terms of the Merger A subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola’s common stock at a price of $18 per share in cash. The tender offer is subject to customary conditions including the tender of …

Moderna Submitted an IND for Its mRNA Vaccine Candidate for Novel Coronavirus  Moderna (MRNA) announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its mRNA vaccine candidate, mRNA-1273, against the novel coronavirus, SARS-CoV-2. The filing is for the evaluation in Phase 2 and for late-stage studies if supported by safety data from the Phase …

Compugen: In the NEWS Compugen (CGEN) was granted a new patent for the composition of COM701 or backup antibodies for the treatment of cancer by the European Patent Office (EPO). The EPO Patent No. 3295951 titled, “Anti-PVRIG Antibodies and Methods of Use”, covers the composition of matter for COM701 and backup antibodies including any anti-PVRIG antibody having the binding fragments of COM701 or backup antibodies …

Gilead Sciences Gilead (GILD) stock soared after market hours adding $11 to the $1.90 the stock had gained during trading hours. Investors’ enthusiasm was raised when very promising results came out of a clinical trial for Gilead’s drug remdesivir given to COVID-19 infected people.   According to the news the University of Chicago’s Phase 3 trial results demonstrated that most COVID-19 infected patients treated with …

Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting Compugen (CGEN) announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG for the treatment of advanced solid tumors, in an oral presentation at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I …

Coronavirus: The Possible Treatments While Moderna’s (MRNA) vaccine is being tested and its stock price continued to rise in the worst market performance day; other companies demonstrated readiness to bring their vaccines against the life-threatening virus into human clinical trials in the next few months. Regeneron (REGN) is one of the most trusted companies. In collaboration with Sanofi (SNY) the companies are on the top of …

Gilead Sciences to Acquire Forty Seven Gilead Sciences (GILD) and Forty Seven (FTSV) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash. The transaction, which values Forty-Seven at approximately $4.9 billion, was unanimously approved by both the Gilead and Forty Seven Boards of Directors and is anticipated to close during the second quarter …

Moderna Therapeutics Among all the firms announcing their interest in working towards designing and producing a preventive vaccine for COVID-19 only Moderna (MRNA) has accomplished that job and delivered it to the health authorities to decide upon the next step. Moderna’s stock soared. The stock did not go up in expectation of the millions . . . This content is for paid subscribers. Please click here …

Gilead and Moderna Stocks Will Outperform Today As stated in Prohost Letter #439 Gilead (GILD) investigational product remdesivir has offered hope towards treating infected people with COVID-19. Regarding the possibility of rapidly designing, creating and developing a preventive vaccine against COVID-19 Moderna Therapeutics (MRNA) seems to have accomplished this task. That’s why we were confident that Gilead’s and Moderna’s stocks will outperform today in a …

CRISPR, Intellia and Editas CRISPR Therapeutics (CRSP) announced revenues of Q4 2019 that beat analysts’ expectations. Based on the good news the stock market’s technicians contributed to boosting the stock’s price enabling the stock to recuperate a large part of its unwarranted recent selloff losses. New investors, who finally heard about the CRISPR gene editing technique and the Companies that specialize in it, seem to …

Coronavirus On January 7, 2020, a novel coronavirus (2019-nCoV) was identified in humans in Wuhan City, Hubei Province, China. Additional cases have been found in the United States and in a growing number of countries around the world.    Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses are …

Nektar Therapeutics and Bristol-Myers Squibb Agreement Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) announced their agreement for a new joint development plan aimed at advancing the combination of Nektar’s bempegaldesleukin (bempeg) + Bristol-Myers’ Opdivo (nivolumab) into multiple new registrational trials. The decision is based on a revision of the strategic collaboration agreement. It includes a new plan where both firms will expand the active clinical development …

Cassava Sciences Stock is Rallying Cassava Sciences (SAVA) stock closed on Friday, December 27, 2019 at $5.21, reaching a 52-week high. Today, December 30, 2019 the stock is jumping higher, trading now at $6.40, UP $1.19 despite the underperforming market today. The reason for investors’ rush to buy the stock is due to the good news from a Phase 2 trial of Cassava’s Alzheimer Disease …